Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + TACE in localized unresectable HCC
NCT00576199Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2008
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Feb 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00576199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00576199.